LISBON, Jan 15 (Reuters) - U.S. private equity fund Lone Star and Portuguese authorities are set to share 1.3 billion euros ($1.34 billion) when Novo Banco makes its first dividend payout in the ...

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Bad news for Novo Nordisk (NVO 2.14%) Friday was good news for Eli Lilly (LLY 0.25%) and Viking Therapeutics (VKTX 2.74%), its two main rivals in the field of weight loss drugs. This morning, Novo ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

The Food and Drug Administration has finalized its decision to call an end to the drug shortage of Eli Lilly's (LLY) blockbuster GLP-1 products, often referred to by their formula name ...

CEO Lars Fruergaard Joergensen delivers a statement during a presentation of the new production site ... [+] of Novo Nordisk "Site Odense" in Kroghs park in Odense, Denmark, on December 16, 2024 ...

Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema ...